Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will present a corporate overview and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference in New York and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.
The Jefferies presentation is on June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is on June 8, 2026 at 11:20 AM ET. Live webcasts and 90-day replays will be available via Corvus' investor relations website.
Details
News Market Reaction – CRVS
On May 21, the first trading day after this news, CRVS closed 7.30% above the previous close.
Data tracked by StockTitan Argus for the May 21 session.
Key Figures
- Jefferies presentation time
- 3:45 PM ET
- June 3, 2026 Jefferies Global Healthcare Conference
- Goldman Sachs presentation time
- 11:20 AM ET
- June 8, 2026 Goldman Sachs Global Healthcare Conference
- Webcast availability
- 90 days
- Duration webcasts remain accessible after the conferences
- Current price
- $11.50
- Pre-news price with 24h change of 8.09%
- 52-week range
- $3.38 – $26.95
- Price is 240.24% above low and 57.33% below high
Historical Context
-
Final Phase 1 soquelitinib atopic dermatitis data with strong efficacy and safety.
-
Q1 2026 results, positive clinical progress, and cash runway into Q2 2028.
-
Appointment of experienced immunology leader Andrew C. Chan to Board.
-
Announcement of May 14 investor meeting on final Phase 1 soquelitinib data.
-
Q4/FY 2025 update and public offering extending cash runway into Q2 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2026 Jefferies Global Healthcare Conference, to be held in New York, NY, and the Goldman Sachs 47th Annual Global Healthcare Conference, to be held in Miami, FL. The Jefferies presentation is scheduled for Wednesday, June 3, 2026 at 3:45 PM ET, and the Goldman Sachs presentation is scheduled for Monday, June 8, 2026 at 11:20 AM ET.
A webcast of the presentations will be available live and for 90 days following the events. The webcasts may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Julia Stern
Real Chemistry
+1-763-350-5223
jstern@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.